US 12,466,870 B2
NY-ESO-1 T cell receptors and methods of use thereof
Robert Babb, River Edge, NJ (US); Natalie Bowerman, Stamford, CT (US); Gang Chen, Yorktown Heights, NY (US); Cagan Gurer, Chappaqua, NY (US); Johanna Hansen, Greenwich, CT (US); Wen-Yi Lee, New Hyde Park, NY (US); Thomas Meagher, Yorktown Heights, NY (US); and David Suh, Midland Park, NJ (US)
Assigned to Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Appl. No. 17/287,643
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
PCT Filed Oct. 23, 2019, PCT No. PCT/US2019/057543
§ 371(c)(1), (2) Date Apr. 22, 2021,
PCT Pub. No. WO2020/086647, PCT Pub. Date Apr. 30, 2020.
Claims priority of provisional application 62/749,194, filed on Oct. 23, 2018.
Prior Publication US 2021/0403527 A1, Dec. 30, 2021
Int. Cl. C07K 14/725 (2006.01); A61K 38/00 (2006.01); A61K 40/11 (2025.01); A61K 40/32 (2025.01); A61K 40/42 (2025.01); C12N 5/0783 (2010.01)
CPC C07K 14/7051 (2013.01) [A61K 40/11 (2025.01); A61K 40/32 (2025.01); A61K 40/4269 (2025.01); C12N 5/0636 (2013.01); A61K 38/00 (2013.01); A61K 2239/48 (2023.05)] 32 Claims
 
1. A T cell receptor (TCR) that binds specifically to an HLA-A2 presented cancer testis antigen New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1) peptide,
wherein the TCR comprises a TCR alpha chain and a TCR beta chain, and
wherein the TCR alpha chain comprises an alpha chain variable domain comprising a complementarity determining region (CDR)1, a CDR2, and a CDR3 comprising the amino acid sequences of SEQ ID NOs: 4, 5, and 6, respectively, and the TCR beta chain comprises a beta chain variable domain comprising a CDR1, a CDR2, and a CDR3 comprising the amino acid sequences of SEQ ID NOs: 1, 2, and 3, respectively.